Merck cholesterol drug cuts heart risk by 9 percent in study

(Reuters) - A large study of Merck & Co Inc's experimental cholesterol drug anacetrapib found that it cut the risk of heart attack and death by a modest 9 percent, which could be due to its affect on bad LDL cholesterol, researchers said on Tuesday.